European equities traded in the US as American depositary receipts were moving lower late Monday morning, declining 0.92% to 1,284.25 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by biopharmaceutical company Cellectis (CLLS) and telecommunications company VEON (VEON), which advanced 12% and 5.8% respectively. They were followed by medical device maker EDAP (EDAP) and petroleum refiner Equinor (EQNR), which rose 2.1% and 0.6% respectively.
The decliners from continental Europe were led by biotech firm Evaxion Biotech (EVAX) and biopharmaceutical company Grifols (GRFS), which fell 12% and 4.2% respectively. They were followed by 3D printer company Materialise (MTLS) and furniture maker Natuzzi (NTZ), which were down 3% and 2.6% respectively.
From the UK and Ireland, the gainers were led by biopharmaceutical companies TC Biopharm (TCBP) and Akari Therapeutics (AKTX), which climbed 11% and 5.5% respectively. They were followed by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and financial services company Lloyds Banking Group (LYG), which were up 3% and 0.2% respectively.
The decliners from the UK and Ireland were led by biopharmaceutical company NuCana (NCNA) and pharmaceutical company Silence Therapeutics (SLN), which dropped 7.1% and 5.2% respectively. They were followed by biotech firm Trinity Biotech (TRIB) and biopharmaceutical company Amarin (AMRN), which lost 3.7% and 2.9% respectively.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。